세계 심장 이식 시장 – 2023-2030

Overview
Global Heart Transplant Market reached US$ YY billion in 2022 and is expected to reach US$ YY billion by 2030, growing with a CAGR of YY% during the forecast period 2023-2030.
Transplanting a healthy donor heart into a patient's body to replace a failing or damaged one is a difficult and life-saving medical surgery. Heart transplantation as a therapeutic option for those with end-stage heart failure or serious cardiac disease continues to advance and be successful for a number of reasons. Heart transplant recipients now enjoy better survival rates and quality of life thanks to improvements in surgical methods, immunosuppressive drugs, and post-transplant care. Both patients and healthcare professionals are motivated by the procedure's success.
The availability of donor hearts has increased as a result of efforts to enlarge the donor pool through programs including awareness campaigns for organ donation, improved methods for obtaining and preserving organs, and the utilization of donors who meet more stringent criteria. The danger of organ rejection has decreased thanks to advances in immune system knowledge and the creation of more potent immunosuppressive drugs, which have also improved transplant recipients' long-term prognoses.
Dynamics
Increasing Research Activities
Growing the scope of research being done on heart transplants has the potential to greatly enhance the results and accessibility of this life-saving treatment. Advanced organ preservation methods that extend the life of donor hearts may be developed as a result of research. the number of potential organ donors can be increased and the possibility of transplantation difficulties can be decreased.
In December 2022, an artificial heart that is ready and available from IIT Kanpur would be very beneficial to those suffering from severe cardiac issues. In critical patients, artificial hearts can be placed. This artificial heart was created by cardiologists from across the nation and IIT Kanpur. Animal trials will begin in February or March. After the study is successful, transplantation can be performed on humans in the next two years. To ease patients' pain, an artificial heart is currently being created.
This artificial heart has been constructed by a group of ten scientists and physicians. Within two years, human heart transplantation will start following the success of the animal trial. In order to create a sophisticated artificial heart, commonly known as a Left Ventricular Assist Device (LVAD), for patients with end-stage heart failure, the School of Medical Research and Technology (SMRT) of IIT Kanpur has established the Hridyantra challenge-based initiative in January 2022.
Active Major Players
The market players are applying market strategies such as product launches and collaboration for the expansion of business in the market. For instance, Werfen and Marengo Asia Hospitals have joined together to make transfusion-free heart transplants available at the hospital. In accordance with the agreement, Marengo Asia Healthcare Group will use Werfen Goal Directed Bleeding Management (GDBM) systems to provide its patients with heart transplants without the need for blood transfusions. Transfusing blood into the patient is a necessity during difficult cardiac surgery procedures.
Implementing the tenets and procedures of Patient Blood Management (PBM), which the WHO strongly advises, will reduce the need for blood transfusions and, as a result, improve patient outcomes (such as a reduction in the length of hospital stay). India is becoming the leading referral location for heart transplants in South Asia as the country's number of heart transplants has increased exponentially.
New Medical Innovation
Heart transplantation is being developed as a result of medical innovation, with the goal of making the surgery safer, easier to access, and more efficient. These advancements in heart transplantation are constantly changing in order to better patient outcomes, shorten waiting periods, and address the problems brought on by organ scarcity.
In January 2022, the first successful transplant of a genetically altered pig's heart into a person was revealed by the University of Maryland School of Medicine and the University of Maryland Medical Center. The patient, a Maryland male, underwent a ground-breaking procedure to save his life, and reports indicate that he is recovering well.
The U.S. Food and Drug Administration does not permit porcine (pig) heart transplants, but in this case, the federal agency authorized the procedure for "compassionate use" because the patient had no other options, according to the medical team.
This medical innovation could aid in resolving the organ shortage issue that prevents thousands of people from receiving vital heart transplants each year. Approximately 20% of people on the heart transplant waiting list pass away while waiting for a transplant or get too ill to be suitable candidates.
Awareness and Education
It is crucial to educate patients and their families about heart failure, its causes, symptoms, and potential treatments. People who are aware of how their heart failure is progressing may seek medical attention and, if necessary, be evaluated for a transplant. For instance, in November 2021, The 'Heart transplant' program and division began operations at Jaslok Hospital & Research Center's Mumbai location.
According to the latest estimates, heart disease is India's number one killer and a silent epidemic. According to data from the Mumbai Municipal Corporation (BMC), over 90 persons in the city pass away from heart attacks each day. According to public records, the city has had a record-breaking 163 heart transplants during the past five years.
Complexity and Risk
Comprehensive patient evaluation is required to identify candidates for cardiac transplantation. To ascertain whether the patient is medically fit for the surgery, this involves evaluating their medical history, general health, and comorbidities. It can be difficult to match a recipient with a matching donor heart. To lower the risk of rejection, variables such as blood type, tissue compatibility, and size matching must be taken into account.
Risks associated with heart transplant surgery include bleeding, infection, and issues with the anaesthetic. Some people can also have problems with the blood vessels or surgical connections. Immunosuppressive medication doesn't completely eliminate the danger of organ rejection, which occurs when the recipient's immune system rejects the transplanted heart because it perceives it as foreign. Rejection episodes might be transient or chronic, and the immunosuppressive regimen may need to be changed.
High Cost
Candidates for heart transplants go through a lengthy evaluation process that involves a range of medical testing, specialist consultations, and diagnostic procedures. These tests are required to analyze a patient's general health and decide whether they are a good candidate for transplantation. These evaluations can be very expensive.
An entire team of highly skilled surgeons, anesthesiologists, nurses, and other medical professionals are needed for the lengthy and intricate heart transplant surgery. The expenses for the surgical team, the operating room space, and the equipment are substantial.
Segment Analysis
The global heart transplant market is segmented based on type, end-user and region.
The artificial heart segment accounted for approximately 54.2% of the market share
The testing artificial heart is the first of its kind created to closely resemble the human heart. Two pumps make up the device, each of which has an atrium, a ventricle, and two mechanical valves. The theory is that by producing a more natural blood flow in this way, problems that can occur with current devices will be diminished.
In July 2023, Swedish hospital Sahlgrenska University Hospital has teamed with Scandinavian company Real Heart AB for clinical studies of their mechanical heart. The business is engaged in the creation of a total artificial heart (TAH) for implantation in heart failure patients. Its TAH features a patented design that is similar to the human heart.
Two atria and two ventricles make up the TAH's four-chamber system, which helps create a physiological blood flow pattern that resembles the body's normal circulation. The business estimates that 60 heart transplants are performed in Sweden each year, but the actual number needed is much higher.
Geographical Penetration
North America accounted for approximately 38.6% of the market share
North America has been a dominant force in the global heart transplant market. According to the American Heart Association, One or both of the heart's ventricles not working properly causes serious heart failure, which is one of the most frequent causes for a heart transplant. A patient who has had a heart transplant has the chance to have a healthy heart with healthy blood flow. If the transplant is successful, cardiac function and blood flow will be more life-sustaining and close to normal.
A new yearly record was set in 2022 with 42,888 organ transplants carried out in the United States, an increase of 3.7% from the previous year. Overall, the number of heart transplants grew by 21.5 percent (4,169 in 2022). Heart transplantation is becoming a recognized treatment for severe heart disease rather than an experimental procedure. In the United States, more than 2,000 heart transplants are carried out annually.
COVID-19 Impact Analysis
The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global Heart Transplant market. Many hospitals and healthcare facilities temporarily delayed or restricted elective surgeries like heart transplants during the early stages of the pandemic. As a result, fewer heart transplant surgeries were carried out.
Due of the possibility of the virus being spread through organ donation, COVID-19 prompted questions about the safety of organ transplantation. To reduce the potential of viral transmission through donated organs, organ procurement organizations (OPOs) and transplant teams had to adopt strict testing and safety standards.
Russia-Ukraine War Impact Analysis
Doctors of medicine, particularly transplant surgeons and cardiologists, may be forced to leave the impacted areas due to the violence. This can lead to a dearth of medical specialists for heart transplants. In conflict-affected areas, organ procurement organizations (OPOs) may encounter difficulties. It can become more challenging to locate and deliver donor organs to transplant facilities, which might cause delays or cancellations of surgical procedures.
Healthcare facilities in crisis zones may redirect financial resources to meet urgent humanitarian and emergency medical requirements. This might restrict funding for specific initiatives like heart transplants.
Key Developments
• In June 2023, Vygon, a business that specializes in the design, manufacturing, and marketing of medical solutions and devices, collaborated with Carmat, a MedTech firm that develops, produces, and sells the Aeson artificial heart.
Competitive Landscape
The major global players in the market include Vygo, SynCardia Systems, LLC, CARMAT, HeartWare International Inc., Calon Cardio, and Others.
Why Purchase the Report?
• To visualize the global heart transplant market segmentation based on type, end-user and region as well as understand critical commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of heart transplant market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global heart transplant market report would provide approximately 41 tables, 43 figures and 186 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies